Anti-Tubercular Activity of Substituted 7-Methyl and 7-Formylindolizines and In Silico Study for Prospective Molecular Target Identification

Venugopala, Katharigatta N.; Tratrat, Christophe; Pillay, Melendhran; Mahomoodally, Fawzi M.; Bhandary, Subhrajyoti; Chopra, Deepak; Morsy, Mohamed A.; Haroun, Michelyne; Al‐Dhubiab, Bandar E.; Attimarad, Mahesh; Nair, Anroop B.; Sreeharsha, Nagaraja; Venugopala, Rashmi; Chandrashekharappa, Sandeep; Alwassil, Osama I.; Odhav, Bharti

doi:10.3390/antibiotics8040247

Cited by 36 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[34][35][36] Herein, we report the anti-TB activity of THP derivatives against H37Rv and multidrug-resistant (MDR) strains of MTB. On the basis of our previous findings on the promising anti-TB activity of THP scaffolds 27,28 on whole-cell anti-TB properties and in a continuous effort to identify novel heterocyclic scaffolds that demonstrate potential anti-TB activity, [37][38][39][40] we screened six 1,2,3,4-tetrahydropyrimidinone (1a-d) and 1,2,3,4-tetrahydropyrimidinethione (2a-b) analogues (Scheme 1) for whole-cell anti-TB activity against H37Rv and MDR strains of MTB by the resazurin microplate assay (REMA) plate method.…”

Section: Introductionmentioning

confidence: 99%

In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against Mycobacterium tuberculosis

Venugopala¹,

Tratrat²,

Pillay³

et al. 2020

DDDT

Self Cite

View full text Add to dashboard Cite

Background and Purpose: Tuberculosis has been reported to be the worldwide leading cause of death resulting from a sole infectious agent. The emergence of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis has made the battle against the infection more difficult since most currently available therapeutic options are ineffective against these resistant strains. Therefore, novel molecules need to be developed to effectively treat tuberculosis disease. Preliminary docking studies revealed that tetrahydropyrimidinone derivatives have favorable interactions with the thymidylate kinase receptor. In the present investigation, we report the synthesis and the mycobacterial activity of several pyrimidinones and pyrimidinethiones as potential thymidylate kinase inhibitors. Methods: The title compounds (1a-d) and (2a-b) were synthesized by a one-pot three-component Biginelli reaction. They were subsequently characterized and used for whole-cell anti-TB screening against H37Rv and multidrug-resistant (MDR) strains of Mycobacterium tuberculosis (MTB) by the resazurin microplate assay (REMA) plate method. Molecular modeling was conducted using the Accelry's Discovery Studio 4.0 client program to explain the observed bioactivity of the compounds. The pharmacokinetic properties of the synthesized compounds were predicted and analyzed. Results: Of the compounds tested for anti-TB activity, pyrimidinone 1a and pyrimidinethione 2a displayed moderate activity against susceptible MTB H37Rv strains at 16 and 32 µg/mL, respectively. Only compound 2a was observed to exert modest activity at 128 µg/mL against MTB strains with cross-resistance to rifampicin and isoniazid. The presence of the trifluoromethyl group was essential to retain the inhibitory activity of compounds 1a and 2a. Molecular modeling studies of these compounds against thymidylate kinase targets demonstrated a positive correlation between the bioactivity and structure of the compounds. The in-silico ADME (absorption, distribution, metabolism, and excretion) prediction indicated favorable pharmacokinetic and drug-like properties for most compounds. Conclusion: Pyrimidinone 1a and pyrimidinethione 2a were identified as the leading compounds and can serve as a starting point to develop novel anti-TB therapeutic agents.

show abstract

Section: Introductionmentioning

confidence: 99%

In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against Mycobacterium tuberculosis

Venugopala¹,

Tratrat²,

Pillay³

et al. 2020

DDDT

Self Cite

View full text Add to dashboard Cite

show abstract

“…The title compound, comprising a substituted indolizine unit, displays a modest activity against susceptible H37Rv strains of Mycobacterium tuberculosis (Venugopala et al, 2019). Besides the tremendous scope of the pharmacological studies on indolizine-based compounds, the substitution of ISSN 2056-9890 fluorine on the benzoyl ring, the presence of flexible moieties and of competitive hydrogen-bond acceptors (namely, oxygen O2 in the ester group at C6 and O3 in the carbonyl group at C8) make the structural study of the title compound of extreme relevance.…”

Section: Chemical Contextmentioning

confidence: 99%

“…The reaction scheme for the synthesis of the title compound. 0.3414 g (88% yield) of the title compound (Venugopala et al, 2019). Suitable single crystals of the compound were grown by the slow evaporation of acetone at ambient conditions.…”

Section: Figurementioning

confidence: 99%

Structural investigation of methyl 3-(4-fluorobenzoyl)-7-methyl-2-phenylindolizine-1-carboxylate, an inhibitory drug towards Mycobacterium tuberculosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

The title compound, C24H18FNO3, crystallizes in the monoclinic centrosymmetric space group P21/n and its molecular conformation is stabilized via C—H...O intramolecular interactions. The supramolecular network mainly comprises C—H...O, C—H...F and C—H...π interactions, which contribute towards the formation of the crystal structure. The different intermolecular interactions have been further analysed via Hirshfeld surface analysis and fingerprint plots.

show abstract

“…In addition, the emergence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) strains, which are highly resistant to most of the currently available anti-TB drugs, trigger the urgent need for the development of novel therapeutic agents to combat these resistant strains [3,4] as only a few drugs are available with United States Food and Drug Administration (US FDA) approval ( Figure 1). Reviews focused on Mycobacterium tuberculosis and in the pursuit of developing novel anti-TB agents, we recently launched a medicinal chemistry program aimed at developing novel, natural [5], cyclic depsipeptides [6] and various heterocyclic scaffolds as potential anti-TB agents [7][8][9][10][11][12][13], including analogues of indolizine such as pyrrolo [1,2-a]quinoline and pyrrolo [1,2-a]isoquinoline, also known as 5,6-benzo-fused indolizine and 7,8-benzo-fused indolizine, respectively [14]. These scaffolds have attracted the attention of medical chemists, as they exhibit a wide variety of pharmacological properties [15].…”

Section: Introductionmentioning

confidence: 99%

Cytotoxicity and Antimycobacterial Properties of Pyrrolo[1,2-a]quinoline Derivatives: Molecular Target Identification and Molecular Docking Studies

et al. 2020

Self Cite

View full text Add to dashboard Cite

A series of ethyl 1-(substituted benzoyl)-5-methylpyrrolo[1,2-a]quinoline-3-carboxylates 4a–f and dimethyl 1-(substituted benzoyl)-5-methylpyrrolo[1,2-a]quinoline-2,3-dicarboxylates 4g–k have been synthesized and evaluated for their anti-tubercular (TB) activities against H37Rv (American Type Culture Collection (ATCC) strain 25177) and multidrug-resistant (MDR) strains of Mycobacterium tuberculosis by resazurin microplate assay (REMA). Molecular target identification for these compounds was also carried out by a computational approach. All test compounds exhibited anti-tuberculosis (TB) activity in the range of 8–128 µg/mL against H37Rv. The test compound dimethyl-1-(4-fluorobenzoyl)-5-methylpyrrolo[1,2-a]quinoline-2,3-dicarboxylate 4j emerged as the most promising anti-TB agent against H37Rv and multidrug-resistant strains of Mycobacterium tuberculosis at 8 and 16 µg/mL, respectively. In silico evaluation of pharmacokinetic properties indicated overall drug-likeness for most of the compounds. Docking studies were also carried out to investigate the binding affinities as well as interactions of these compounds with the target proteins.

show abstract

Anti-Tubercular Activity of Substituted 7-Methyl and 7-Formylindolizines and In Silico Study for Prospective Molecular Target Identification

Cited by 36 publications

References 33 publications

<p>In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against <em>Mycobacterium tuberculosis</em></p>

<p>In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against <em>Mycobacterium tuberculosis</em></p>

Structural investigation of methyl 3-(4-fluorobenzoyl)-7-methyl-2-phenylindolizine-1-carboxylate, an inhibitory drug towards Mycobacterium tuberculosis

Cytotoxicity and Antimycobacterial Properties of Pyrrolo[1,2-a]quinoline Derivatives: Molecular Target Identification and Molecular Docking Studies

Contact Info

Product

Resources

About